There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...

Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...

This is an audio transcript of the FT News Briefing podcast episode: ‘Trump steers the world towards a tax war’ Sonja Hutson Good morning from the Financial Times. Today is Friday, January 24th. And ...

China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why ...

The company’s co-founders are Josh Bilenker, former CEO of Loxo Oncology, a part of Eli Lilly, and Jeffrey Engelman ... The newly formed company’s CEO is Ken Song, who was more recently CEO of ...

We catch up with the stellar singer-songwriter about the process of grounding herself that led to making her sixth album.

Not everything is wavy baby between former Southern Hospitality besties Grace Lilly and Maddi Reese. Grace opened up to ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.